23andMe 裁员 40% 并结束癌症研究以稳定财务状况。 23andMe cuts 40% of its workforce and ends cancer research to stabilize finances.

基因检测公司 23andMe 正在裁员 40%，并停止其治疗部门，包括癌症研究项目，以稳定公司的财务状况。 Genetic testing company 23andMe is cutting 40% of its workforce and discontinuing its therapeutics division, including cancer research programs, in an effort to stabilize the company's financial situation. 作为此次重组的一部分，将失去 200 多个工作岗位。 Over 200 jobs will be lost as part of this restructuring.